HRMY Stock Analysis: Harmony Biosciences Holdings | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.004m USD | 12M Return: 3.6% | US4131971040 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.5M
EPS Trend: 43.6%
Qual. Beats: -1
Rev. Trend: 99.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Harmony Biosciences Holdings (NASDAQ: HRMY) is a U.S.-based, commercial-stage pharmaceutical company focused on developing and commercializing therapies for rare neurological diseases. Its lead marketed product is WAKIX (pitolisant), a first-in-class molecule approved for excessive daytime sleepiness in adults with narcolepsy. The company is headquartered in Plymouth Meeting, Pennsylvania, was incorporated in 2017, and went public in August 2020.
Beyond WAKIX, Harmony is advancing a pipeline that includes pitolisant in multiple indications-Prader-Willi Syndrome (Phase 3), Myotonic Dystrophy type 1 (Phase 2), and Gastro-Resistant/High-Dose formulations (Phase 2)-alongside earlier-stage assets such as an orexin-2 receptor agonist (BP1.15205) and an MCHR1 antagonist (HBS-102). The company is also developing ZYN-002 in a Phase 3 registrational trial for Fragile X Syndrome, with work also targeting 22q Deletion Syndrome, and a portfolio of central nervous system candidates (EPX-100, EPX-200, CBS105, CBS104) aimed at developmental and epileptic encephalopathies, Dravet and Lennox-Gastaut syndromes, treatment-resistant narcolepsy, and refractory epilepsy.
As a rare-disease specialty pharmaceutical company, Harmonys business model centers on commercializing high-margin, orphan and specialty neurology drugs in the U.S., leveraging favorable regulatory designations (orphan drug, breakthrough therapy) and concentrated prescriber networks to support pricing power and patient access. Rare-disease therapies typically target small patient populations with limited competition, but rely on continued pipeline advancement to sustain long-term growth beyond lead-asset exclusivity.
- WAKIX sales growth drives narcolepsy market share gains
- Pitolisant Phase 3 Prader-Willi Syndrome data readout approaches
- Competition from Xywav and Sunosi pressures WAKIX pricing
| Net Income: 178.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.22 > 0.02 and ΔFCF/TA -2.73 > 1.0 |
| NWC/Revenue: 67.04% < 20% (prev 74.51%; Δ -7.47% < -1%) |
| CFO/TA 0.22 > 3% & CFO 323.0m > Net Income 178.6m |
| Net Debt (-622.0m) to EBITDA (271.2m): -2.29 < 3 |
| Current Ratio: 3.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.7m) vs 12m ago 1.64% < -2% |
| Gross Margin: 74.03% > 18% (prev 77.70%; Δ -3.67% > 0.5%) |
| Asset Turnover: 73.66% > 50% (prev 68.36%; Δ 5.29% > 0%) |
| Interest Coverage Ratio: 19.03 > 6 (EBIT TTM 245.9m / Interest Expense TTM 12.9m) |
| A: 0.45 (Total Current Assets 934.8m - Total Current Liabilities 271.5m) / Total Assets 1.48b |
| B: 0.21 (Retained Earnings 317.0m / Total Assets 1.48b) |
| C: 0.18 (EBIT TTM 245.9m / Avg Total Assets 1.34b) |
| D: 2.64 (Book Value of Equity 1.07b / Total Liabilities 406.0m) |
| Altman-Z'' = 7.65 = AAA |
| DSRI: 1.06 (Receivables 127.7m/100.7m, Revenue 989.4m/825.9m) |
| GMI: 1.05 (GM 77.70% / 74.03%) |
| AQI: 1.20 (AQ_t 0.36 / AQ_t-1 0.30) |
| SGI: 1.20 (Revenue 989.4m / 825.9m) |
| TATA: -0.10 (NI 178.6m - CFO 323.0m) / TA 1.48b) |
| Beneish M = -2.68 (Cap -4..+1) = A |
As of November 06, 2026, the stock is trading at USD 32.47 with a total of 1,477,499 shares traded. Over the past week, the price has changed by -15.86%, over one month by -18.66%, over three months by -15.09% and over the past year by +3.57%.
Current recommended Stop Loss: 27.50 (which is 15.3% or 2.8 ATR below the current price).
Harmony Biosciences Holdings has received a consensus analysts rating of 4.08. Therefore, it is recommended to buy HRMY.
- StrongBuy: 6
- Buy: 2
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 48.1 | 48.1% |
P/E Trailing = 11.3957
P/E Forward = 9.1996
P/S = 2.0879
P/B = 2.1581
Revenue TTM = 989.4m USD
EBIT TTM = 245.9m USD
EBITDA TTM = 271.2m USD
Long Term Debt = 143.7m USD (from longTermDebt, last fiscal year)
Short Term Debt = 20.0m USD (from shortTermDebt, last quarter)
Debt = 149.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -622.0m USD (calculated: Debt 149.1m - CCE 771.1m)
Enterprise Value = 1.38b USD (2.00b + Debt 149.1m - CCE 771.1m)
Interest Coverage Ratio = 19.03 (Ebit TTM 245.9m / Interest Expense TTM 12.9m)
EV/FCF = 4.28x (Enterprise Value 1.38b / FCF TTM 322.9m)
FCF Yield = 23.36% (FCF TTM 322.9m / Enterprise Value 1.38b)
FCF Margin = 32.64% (FCF TTM 322.9m / Revenue TTM 989.4m)
Net Margin = 18.05% (Net Income TTM 178.6m / Revenue TTM 989.4m)
Gross Margin = 74.03% ((Revenue TTM 989.4m - Cost of Revenue TTM 256.9m) / Revenue TTM)
Gross Margin QoQ = 70.00% (prev 75.81%)
Tobins Q-Ratio = 0.94 (Enterprise Value 1.38b / Total Assets 1.48b)
Interest Expense / Debt = 8.67% (Interest Expense 12.9m / Debt 149.1m)
Taxrate = 23.33% (54.4m / 233.0m)
NOPAT = 188.5m (EBIT 245.9m * (1 - 23.33%))
Current Ratio = 3.44 (Total Current Assets 934.8m / Total Current Liabilities 271.5m)
Debt / Equity = 0.14 (Debt 149.1m / totalStockholderEquity, last quarter 1.07b)
Debt / EBITDA = -2.29 (Net Debt -622.0m / EBITDA 271.2m)
Debt / FCF = -1.93 (Net Debt -622.0m / FCF TTM 322.9m)
Total Stockholder Equity = 963.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.30% (Net Income 178.6m / Total Assets 1.48b)
RoE = 18.55% (Net Income TTM 178.6m / Total Stockholder Equity 963.0m)
RoCE = 22.22% (EBIT 245.9m / Capital Employed (Equity 963.0m + L.T.Debt 143.7m))
RoIC = 16.01% (NOPAT 188.5m / Invested Capital 1.18b)
WACC = 7.42% (E(2.00b)/V(2.15b) * Re(7.48%) + D(149.1m)/V(2.15b) * Rd(8.67%) * (1-Tc(0.23)))
Discount Rate = 7.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.01 | Cagr: 1.63%
[DCF] Terminal Value 76.52% ; FCFF base≈312.5m ; Y1≈336.6m ; Y5≈410.2m
[DCF] Fair Price = 118.7 (EV 6.29b - Net Debt -622.0m = Equity 6.91b / Shares 58.2m; r=8.35% [WACC [floored]]; 5y FCF grow 8.77% → 2.50% )
EPS Correlation: 43.59 | EPS CAGR: 5.25% | SUE: -0.86 | # QB: -1
Revenue Correlation: 99.88 | Revenue CAGR: 21.11% | SUE: -0.46 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.83 | Chg30d=+0.00% | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=5.22 | Chg30d=+0.00% | Revisions=+17% | GrowthEPS=+45.1% | GrowthRev=+18.2%
EPS next Year (2027-12-31): EPS=7.00 | Chg30d=+4.76% | Revisions=-17% | GrowthEPS=+34.1% | GrowthRev=+13.7%
[Analyst] Revisions Ratio: +0% (up=5, down=5)